Neobe Therapeutics


While immunotherapies have revolutionized the treatment of cancer, the large majority of patients with solid tumours still do not respond to them. Neobe is developing a platform for the engineering of programmable live biotherapeutics, which can colonize solid tumours and remodel their local microenvironment. By removing barriers to immune infiltration in a safe and localized way, Neobe's recombinant live biotherapeutics can potentially double the number of cancer patients that respond to existing immunotherapeutic strategies.

Be part of SBC Catalyser Programme!

Spaces are limited to 10 companies per cohort. Contact Marco to get more information on our next programme in spring 2024.

Contact Marco

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.